company background image
ALA

Arovella Therapeutics ASX:ALA Stock Report

Last Price

AU$0.026

Market Cap

AU$17.5m

7D

8.3%

1Y

-25.7%

Updated

04 Dec, 2022

Data

Company Financials +
ALA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

ALA Stock Overview

Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally.

Arovella Therapeutics Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Arovella Therapeutics
Historical stock prices
Current Share PriceAU$0.026
52 Week HighAU$0.055
52 Week LowAU$0.02
Beta-1.13
1 Month Change0%
3 Month Change8.33%
1 Year Change-25.71%
3 Year Change-60.61%
5 Year Change-93.50%
Change since IPO-99.41%

Recent News & Updates

Recent updates

We're Hopeful That Suda Pharmaceuticals (ASX:SUD) Will Use Its Cash Wisely

Jul 01
We're Hopeful That Suda Pharmaceuticals (ASX:SUD) Will Use Its Cash Wisely

Shareholder Returns

ALAAU PharmaceuticalsAU Market
7D8.3%-4.4%0.6%
1Y-25.7%-23.7%-1.8%

Return vs Industry: ALA underperformed the Australian Pharmaceuticals industry which returned -23.7% over the past year.

Return vs Market: ALA underperformed the Australian Market which returned -1.8% over the past year.

Price Volatility

Is ALA's price volatile compared to industry and market?
ALA volatility
ALA Average Weekly Movement14.7%
Pharmaceuticals Industry Average Movement10.2%
Market Average Movement9.0%
10% most volatile stocks in AU Market15.9%
10% least volatile stocks in AU Market4.1%

Stable Share Price: ALA is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: ALA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
1999n/aMichael Bakerhttps://www.arovella.com

Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat short-term insomnia, which is marketed under the brand name of Ambien or Stilnox; invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer; OroMist, an oro-mucosal technology that delivers a range of drug classes through the cheeks, gums, tongue, or floor of the mouth; and Anagrelide to treat cancer. The company also develops oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.

Arovella Therapeutics Limited Fundamentals Summary

How do Arovella Therapeutics's earnings and revenue compare to its market cap?
ALA fundamental statistics
Market CapAU$17.48m
Earnings (TTM)-AU$8.62m
Revenue (TTM)AU$299.66k

59.1x

P/S Ratio

-2.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALA income statement (TTM)
RevenueAU$299.66k
Cost of RevenueAU$207.06k
Gross ProfitAU$92.60k
Other ExpensesAU$8.71m
Earnings-AU$8.62m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.013
Gross Margin30.90%
Net Profit Margin-2,876.84%
Debt/Equity Ratio0%

How did ALA perform over the long term?

See historical performance and comparison